Every 10-Q that VivoSim Labs Inc (VIVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VIVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIVS filings page.
VivoSim Labs, Inc. reported a small revenue base and ongoing losses while strengthening liquidity after quarter‑end. For the quarter ended June 30, 2026, royalty revenue was $18,000 versus $37,000 a year earlier, reflecting dependence on a single IP licensing customer. Research and development expense was $1.1 million and selling, general and administrative expense was $1.6 million, leading to an operating loss of $2.8 million. A $1.4 million gain from remeasuring common stock warrant liabilities reduced the net loss to $1.3 million, compared with a $2.8 million net loss in the prior‑year period.
At June 30, 2026, cash and cash equivalents were $1.7 million with total assets of $3.8 million, liabilities of $6.2 million, and a stockholders’ deficit of $2.3 million. Operating cash outflow was $3.2 million for the quarter, and management expects fiscal 2027 operating expense of $10.7 million. The company states that these factors and its accumulated deficit of $357.3 million raise substantial doubt about its ability to continue as a going concern without additional financing. Subsequent to quarter‑end, VivoSim received $6.0 million tied to the FXR314 asset sale and completed a $4.0 million private placement, and all 3,947,369 2026 Common Warrants were exercised, eliminating the related $4.3 million warrant liability.
VivoSim Labs, Inc. reported very modest revenue and continued losses for the quarter ended December 31, 2025 while disclosing substantial doubt about its ability to continue as a going concern.
Quarterly revenue was about $26,000, all from royalty income, and the company posted a net loss of roughly $2.7 million, narrower than the prior year’s loss. For the first nine months of fiscal 2026, the net loss reached about $8.1 million.
Cash and cash equivalents fell to roughly $4.3 million at December 31, 2025 from $11.3 million at March 31, 2025, driven by about $8.6 million of negative operating cash flow, partially offset by $1.8 million of at-the-market equity proceeds and prior FXR program sale proceeds. Management states that, under its current operating plan, additional capital will be needed and current conditions raise substantial doubt about its ability to fund operations for at least one year after issuance of these financial statements.
VivoSim Labs (VIVS) filed its Q2 FY2026 10‑Q, reporting a net loss of $2.545 million for the quarter ended September 30, 2025, on $28,000 in royalty revenue. Operating expenses totaled $2.663 million, led by research and development of $923,000 and selling, general and administrative of $1.740 million. Other income contributed $92,000.
Liquidity remains tight. Cash and cash equivalents were $6.677 million with total assets of $9.686 million and stockholders’ equity of $7.065 million. Net cash used in operating activities was $6.318 million for the six months. The company raised approximately $1.8 million during the six months via its ATM, issuing 701,729 shares. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
During March 2025, the company sold its FXR program for $10.0 million (with $1.0 million in escrow and potential milestones up to $50.0 million). As of November 1, 2025, 2,607,962 shares were outstanding. The company recorded a $0.6 million accrual related to an ongoing legal matter.
VivoSim Labs reports a quarter of continued transition from clinical-stage drug development to a services and preclinical discovery business. Revenue was minimal at $37,000 from royalties while product revenue ceased following the winding down of Mosaic. The company recorded a $2.843 million net loss for the three months ended June 30, 2025 and cash and cash equivalents declined to $9.1 million, with total assets of $11.98 million and working capital of about $7.6 million.
In March 2025 VivoSim sold its FXR program for $10.0 million ($9.0M at closing, $1.0M in escrow and up to $50.0M in milestone payments). Management disclosed substantial doubt about going concern for the next year and expects to require additional financing; it reported net cash used in operations of $3.94 million in the quarter. The company highlights scientific progress: its liver NAM platform showed 87.5% sensitivity and 100% specificity on a test set presented in May 2025. Management forecasts fiscal 2026 operating expenses of $10–11 million and continues to sell shares through its ATM program.